pISSN 2093-2340   eISSN 2092-6448
Indexed in ESCI, PubMed, Scopus, DOAJ and more
Open Access, Peer-reviewed
    Infect Chemother. 2010 Aug;42(4):209-215. Korean.
    Published online Aug 30, 2010.
    https://doi.org/10.3947/ic.2010.42.4.209
    Copyright © 2010 by The Korean Society of Infectious Diseases and Korean Society for Chemotherapy
    Review

    Current Usage and Prospect of New Antifungal agents in Korea

    Sang Il Kim and Moon Won Kang
      • Division of Infectious Disease, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
    • Correspondence to Moon Won Kang, M.D. Division of Infectious Disease, Department of Internal Medicine, Seoul St. Mary's Hospital, #505, Banpo-dong, Seocho-gu, Seoul 137-040, Korea. Tel: +82-2-2258-6001, Fax: +82-2-3477-9193, Email: infect@catholic.ac.kr
    Received August 03, 2010; Accepted August 03, 2010.

    This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Abstract

    The incidence of invasive fungal infections has been increased worldwide along with the increasing population at high risk for fungal infection. However, no data is available for the current status of usage of antifungal agents in Korea. We described the usage of antifungal agents including second-generation triazole and echinocandins that have been recently introduced. Data from Health Insurance Review and Assessment Service were analyzed. Estimated total DDDs (daily defined doses)/1,000 patient-day of parenteral antifungal agents were 187.6 in 2008 and 143.2 in 2007 and annual rates of increase was 20% to 30% since 2004. Indeed, increased percentage of newer agents were observed. Changes of the treatment guidelines and the regulations for insurance coverage are considered to influence the trend of antifungal usage.

    Keywords
    Usage of antifungal agents; Trend; Korea

    Figures

    Figure 1
    Estimated total DDDs (daily defined doses)/1,000 patient-day of parenteral antifungal agents were 187.6 in 2008 and 143.2 in 2007. Annual increment was 20% to 30% since 2004.

    VCZ, voriconazole; CSFG, caspofungin; ICZ, itraconazole; FCZ, fluconazole; ABLC, amphotericin B lipid complex; AMB, amphotericin B

    Figure 2
    Tornado diagrams of sensitivity analysis on change in ICER (incremental cost- effectiveness ratio) for clinical success and survival after treatment. Adopted from; Jo CI, Jun S, Kim SI. An economic evaluation of anidulafungin in the treatment of invasive candidiasis in Korea. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 3rd Asia-Pacific Conference; September 7-9, 2008; Seoul, Korea

    Tables

    Table 1
    Approved Dates, Product Types, and Indications of New Antifungal agents by KFDA (Korean Food and Drug Administration)a

    Table 2
    Amount of New Antifungal agents Requested for Reimbursement to National Health Insurance Corporation by Year

    Table 3
    Amounts of Antifungal agents Imported in Korea by Year

    Table 4
    Amounts (Numbers of Vials) of Parenteral Antifungal agents that are Requested for Reimbursement in Korea by Year

    Table 5
    Measured DDDs (defined daily doses)/1,000 Patient-day and Percentage of Each Drug among Total Parenteral Antifungal Agents in Korea

    References

      1. Kang MW. Triazole antifungal drugs. Korean J Infect Dis 1990;22:1–4.
      1. Woo JH, Chung DR, Ryu J. Systemic antifungal agents. Korean J Med Mycol 1997;2:110–122.
      1. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–415.
      1. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, de Pauw BE. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391–1402.
      1. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407–1416.
      1. Merlo J, Wessling A, Melander A. Comparison of dose standard units for drug utilisation studies. Eur J Clin Pharmacol 1996;50:27–30.
      1. Cosentino M, Leoni O, Banfi F, Lecchini S, Frigo G. An approach for the estimation of drug prescribing using the defined daily dose methodology and drug dispensation data. Theoretical considerations and practical applications. Eur J Clin Pharmacol 2000;56:513–517.
      1. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764–771.
      1. Fischer T, Heussel G, Huber C. Liposomal amphotericin B for fever and neutropenia. N Engl J Med 1999;341:1152.
      1. Prentice HG, Kibbler CC. Liposomal amphotericin B for fever and neutropenia. N Engl J Med 1999;341:1152–1153.
      1. Rakita R. Liposomal amphotericin B for fever and neutropenia. N Engl J Med 1999;341:1153–1154.
      1. Kontoyiannis DP, Lewis RE. Caspofungin versus liposomal amphotericin B for empirical therapy. N Engl J Med 2005;352:410–414.
      1. Kim EC, Kim JS, Jung HJ. In vitro activity of antifungal agents against clinical isolates of yeasts. J Korean Soc Chemother 1998;16:215–220.
      1. Lee MK, Kim HR, Kang JO, Kim MN, Kim EC, Kim JS, Kim JJ, Park YJ, Song W, Shin JH, Lee KM, Lee NY, Lee M, Lee WG, Lee CK, Lee HJ, Chang CL, Choi TY. Susceptibility and trailing growth of Candida albicans to fluconazole: results of a Korean multicentre study. Mycoses 2007;50:148–149.
      1. Lee JS, Shin JH, Lee K, Kim MN, Shin BM, Uh Y, Lee WG, Lee HS, Chang CL, Kim SH, Shin MG, Suh SP, Ryang DW. Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea. Yonsei Med J 2007;48:779–786.
      1. Kim SH, Shin JH, Kim EC, Lee K, Kim MN, Lee WG, Uh Y, Lee HS, Lee MK, Jeong SH, Jung SI, Park KH, Lee JS, Shin MG, Suh SP, Ryang DW. The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study. Med Mycol 2009;47:296–304.
      1. Blot S, Janssens R, Claeys G, Hoste E, Buyle F, De Waele JJ, Peleman R, Vogelaers D, Vandewoude K. Effect of fluconazole consumption on long-term trends in candidal ecology. J Antimicrob Chemother 2006;58:474–477.
      1. Park JY, Shin JH, Uh Y, Kim EC, Kee SJ, Kim SH, Shin MG, Suh SP, Ryang DW. In vitro amphotericin B susceptibility of Korean bloodstream yeast isolates assessed by the CLSI broth microdilution method, Etest, and minimum fungicidal concentration test. Korean J Lab Med 2008;28:346–352.
      1. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008;56:126–129.
      1. Moeremans K, Annemans L, Ryu JS, Choe KW, Shine WS. Economic evaluation of intravenous itraconazole for presumed systemic fungal infections in neutropenic patients in Korea. Int J Hematol 2005;82:251–258.
    Cited by
    Crossref 6
    Google Scholar 
    MeSH Terms
    Antifungal Agents
    Dichlorodiphenyldichloroethane
    Echinocandins
    Incidence
    Insurance Coverage
    Insurance, Health
    Korea
    Social Control, Formal
    Metrics
    Share
    Figures
    slide
    slide

    1 / 2

    Tables
    slide
    slide
    slide
    slide
    slide

    1 / 5

    PERMALINK